IMR Press / FBL / Volume 20 / Issue 8 / DOI: 10.2741/4368

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Lactic dehydrogenase and cancer: an overview
Show Less
1 Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, via Pansini, 5, 80131 Naples, Italy
2 Department of Biochemistry, Biophysics and General Pathology. Second University of Naples, Medical School, Via L. De Crecchio 7, 80138 Naples, Italy
3 Department of Chemical Sciences, University of Naples Federico II, via Cintia 21, 80126 Naples, Italy
4 Department of Advanced Biomedical Sciences, University of Naples Federico II, via Pansini, 5, 80131 Naples, Italy
Front. Biosci. (Landmark Ed) 2015, 20(8), 1234–1249;
Published: 1 June 2015

Despite the intense scientific efforts made, there are still many tumors that are difficult to treat and the percentage of patient survival in the long-term is still too low. Thus, new approaches to the treatment of cancer are needed. Cancer is a highly heterogeneous and complex disease, whose development requires a reorganization of cell metabolism. Most tumor cells downregulate mitochondrial oxidative phosphorylation and increase the rate of glucose consumption and lactate release, independently of oxygen availability (Warburg effect). This metabolic rewiring is largely believed to favour tumor growth and survival, although the underlying molecular mechanisms are not completely understood. Importantly, the correlation between the aerobic glycolysis and cancer is widely regarded as a useful biochemical basis for the development of novel anticancer strategies. Among the enzymes involved in glycolysis, lactate dehydrogenase (LDH) is emerging as a very attractive target for possible pharmacological approaches in cancer therapy. This review addresses the state of the art and the perspectives concerning LDH both as a useful diagnostic marker and a relevant molecular target in cancer therapy and management.

Aerobic Glycolysis
Energy Metabolism
Drug Target
Cancer Therapy
Tumor Marker
Back to top